RedHill Biopharma (RDHL) Income from Continuing Operations (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of Income from Continuing Operations data on file, last reported at 58921000.0 in Q2 2023.

• On a quarterly basis, Income from Continuing Operations rose 791.8% year-over-year to 58921000.0 in Q2 2023; TTM through Jun 2023 was 40004000.0, a 60.47% increase from a year earlier, with the FY2025 full-year figure at 429000.0, up 94.81% from the prior year.
• Income from Continuing Operations for Q2 2023 stood at 58921000.0, up from 7919000.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for RDHL reached as high as 58921000.0 in Q2 2023 and fell as low as 133951000.0 in Q4 2021.
• Historically, Income from Continuing Operations has averaged 271388.89 across 5 years, with a median of 11059500.0 in 2019.
• Across the five-year window, Income from Continuing Operations sank 714.12% in 2021 and surged 791.8% in 2023, its largest moves.
• Year by year, Income from Continuing Operations stood at 11837000.0 in 2019, then soared by 84.27% to 21812000.0 in 2020, then sank by 714.12% to 133951000.0 in 2021, then surged by 48.1% to 69521000.0 in 2022, then surged by 184.75% to 58921000.0 in 2023.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were 58921000.0 in Q2 2023, 7919000.0 in Q1 2023, and 69521000.0 in Q4 2022.